Findings

What do systematic reviews say?

1,520 questions · 1,575 findings · 175 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 239 · 15.2%GRADE not reported 59 · 3.7%Very low 337 · 21.4%Low 406 · 25.8%Moderate 410 · 26%High 124 · 7.9%

Corticosteroids vs placebo

Clinical improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 475 participants
Low

Corticosteroids vs placebo

Histological improvement (dichotomous) · active EoE patients

Corticosteroids leads to higher histological improvement (dichotomous) compared with placebo (high certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 11.94 [6.56, 21.75]
12 studies · 978 participants
High

Corticosteroids vs placebo

Histological improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 449 participants
Low

Corticosteroids vs placebo

Endoscopic improvement (dichotomous) · active EoE patients

Corticosteroids showed no clear difference in endoscopic improvement (dichotomous) compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.6 [0.82, 8.19]
3 studies · 102 participants
Low

Corticosteroids vs placebo

Endoscopic improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 596 participants
Low

Corticosteroids vs placebo

Withdrawals due to adverse events · active EoE patients

Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.64 [0.43, 0.96]
14 studies · 1032 participants
Low

Corticosteroids vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether corticosteroids changes clinical improvement (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.17 [0.75, 6.27]
2 studies · 252 participants
Very low

Corticosteroids vs placebo

Clinical improvement (continuous) · inactive EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 269 participants
Very low

Corticosteroids vs placebo

Vomiting ‐ intraoperative · women undergoing regional anaesthesia for caesarean section

It is very uncertain whether corticosteroids changes vomiting ‐ intraoperative compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
RR 0.52 [0.31, 0.87]
6 studies · 609 participants
Very low

Corticosteroids vs placebo

Nausea · women undergoing regional anaesthesia for caesarean section

Corticosteroids probably leads to lower nausea ‐ postoperative compared with placebo (moderate certainty).

2 findings from 1 review

Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
RR 0.59 [0.49, 0.73]
6 studies · 733 participants
Moderate
Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
RR 0.56 [0.37, 0.83]
6 studies · 609 participants
Very low

Corticosteroids vs placebo

Vomiting ‐ postoperative · women undergoing regional anaesthesia for caesarean section

Corticosteroids may leads to lower vomiting ‐ postoperative compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
RR 0.68 [0.49, 0.95]
7 studies · 793 participants
Low

Corticosteroids vs placebo

AHI · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 75 participants
Low

Corticosteroids vs placebo

Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 75 participants
Moderate

Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 75 participants
Low

Corticosteroids vs placebo

Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 75 participants
Moderate

Corticosteroids vs placebo

Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐inflammatory medications for obstructive sleep apnoea in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs control

Early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28; day 60; and in hospital · adults with acute respiratory distress syndrome

Corticosteroids showed no clear difference in early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28;… compared with control (low certainty).

1 finding from 1 review

Pharmacological agents for adults with acute respiratory distress syndrome 2019 · Cochrane Headline outcomes only
RR 0.77 [0.57, 1.05]
6 studies · 574 participants
Low

Corticosteroids vs control

Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome

It is very uncertain whether corticosteroids changes late all‐cause mortality ( > 3 months) Reported at: 180 days compared with control (very low certainty).

1 finding from 1 review

Pharmacological agents for adults with acute respiratory distress syndrome 2019 · Cochrane Headline outcomes only
RR 0.99 [0.64, 1.52]
1 study · 180 participants
Very low

Corticosteroids vs control

Duration of mechanical ventilation · adults with acute respiratory distress syndrome

1 finding from 1 review

Pharmacological agents for adults with acute respiratory distress syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 277 participants
Very low

Corticosteroids vs control

Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome

1 finding from 1 review

Pharmacological agents for adults with acute respiratory distress syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 494 participants
Low